News | January 01, 2026
Wockhardt’s WCK 5222 earns accelerated review from European Medicines Agency
The accelerated review covers WCK 5222 for multiple critical infections
The accelerated review covers WCK 5222 for multiple critical infections
Harbour BioMed brings advanced antibody discovery platforms to the table
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
MRI is particularly valuable in pediatric care due to its non-invasive nature
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Subscribe To Our Newsletter & Stay Updated
